Research programme: cyclin-dependent kinase inhibitors - Cyclacel Pharmaceuticals
Alternative Names: 2-Anilino-4-(thiazol-5-yl)-pyrimidine - Cyclacel Pharmaceuticals; CCT-68127; CYC 11056; CYC400 series - Cyclacel Pharmaceuticals; Second-generation CDK inhibitors - Cyclacel Pharmaceuticals; Tri-substituted purines - Cyclacel PharmaceuticalsLatest Information Update: 10 Mar 2023
At a glance
- Originator Cyclacel Pharmaceuticals
- Class Purines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors; Cyclin-dependent kinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Cancer; Glomerulonephritis; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 10 Mar 2023 Discontinued - Preclinical for Neuroblastoma in United Kingdom (PO)
- 23 Feb 2023 Discontinued - Preclinical for Acute myeloid leukaemia in United Kingdom (PO)
- 23 Feb 2023 Discontinued - Preclinical for Cancer in United Kingdom (IV)